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Abstract
Background: Warfarin is highly efficacious in reducing stroke risk in patients with atrial 
fibrillation (AF). However, its safety and efficacy in stroke prevention is markedly influenced by 
its time in therapeutic range (TTR). The quality of anticoagulant therapy varies considerably 
among countries. Representative data concerning the quality of anticoagulant therapy and its 
effects on clinical outcomes in Turkey are lacking.
Methods: Warfarin in Therapeutic Range (WATER) registry is a prospective, observational 
study which followed 572 AF patients (mean age 67.3 ± 12 years; females 60%; 71% non-
valvular AF) treated with warfarin. 
Results: At a median of 22-month follow-up, the mean TTR value was 42.3 ± 18% (me-
dian: 40%) for the whole population and lower in non-valvular AF su group than valvular 
AF subgroup (40.3 ± 18 vs. 46.9 ± 19, respectively, p < 0.001). Death, cardiac hospital-
ization and minor bleeding rates were higher in the group with TTR value < 40% than 
the group with > 40% (3.4% vs. 5.9%; 28.6% vs. 35.4%; 36.5% vs. 41.7%, respectively, 
all of them p < 0.001). A correlation analysis showed a negative correlation between age 
and TTR value (r = –0.178, p < 0.001). Mean CHA2DS2VASc score was 3.63 ± 1.5  
and mean HASBLED score was 2.38 ± 1.01 in the non-valvular AF group. A negative cor-
relation was observed between TTR levels and CHA2DS2VASc score.
Conclusions: WATER provides insight into the anticoagulation control status of AF patients 
in Turkey. The quality of anticoagulation was poor. Strategies should be undertaken by clini-
cians and patients to improve TTR. New oral anticoagulant agents may be perfect alternatives 
for non-valvular AF patients. (Cardiol J 2015; 22, 5: 567–575)
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Introduction
Atrial fibrillation (AF) is a common cardiac 
arrhythmia that is predominantly non-valvular 
(NVAF) and its prevalence is likely to markedly 
increase in next several decades [1]. AF is a com-
mon cause of stroke, heart failure, hospitalization, 
and death in affected patients. AF patients have 
a 5-fold increase in the risk of stroke compared to 
individuals of the same age who are in sinus rhythm 
[1, 2]. For decades, warfarin has been the most 
widely utilized anticoagulant for stroke prophylaxis 
among AF patients. Warfarin is highly efficacious 
in reducing stroke risk, with a meta-analysis of 
several clinical trials reporting a 64% decrease 
in stroke risk among NVAF patients treated with 
warfarin [2, 3]. The major impediment to warfarin 
usage is the unpredictability of the level of anti-
coagulation in a given dose. Efficacy and safety 
of warfarin is markedly influenced by its time in 
therapeutic range (TTR), referring to the time 
patients treated with warfarin spend having an 
international normalized prothrombin time ratio 
(INR) within the therapeutic range, which requires 
regular blood test monitoring [4, 5]. A high TTR 
(≥ 70%) is required for warfarin therapy to achieve 
a maximal effect. This reduces the risk of not only 
stroke and systemic embolism, but also bleeding 
[3–6]. Results from randomized clinical trials dem-
onstrate that optimal TTR threshold is reached in 
approximately 60% of cases [7]. However, several 
observational studies and registries conducted on 
AF populations reported that AF patients spend 
only approximately half the TTR of warfarin [5, 8]. 
Lower TTR values in real life patients rather than 
randomized controlled trial patients have been con-
firmed consistently throughout different countries 
[8, 9]. Data on AF epidemiology and management 
in Turkey are quite limited and prospective mild- to 
long-term studies are lacking. In view of this fact, 
we undertook the registry of Warfarin in Therapeu-
tic Range (WATER), a prospective observational 
study of AF in Turkey that enrolled consecutive 
AF patients who received warfarin. The purposes 
of this registry are to observe epidemiological and 
clinical characteristics of the AF population and to 
demonstrate the quality of anticoagulant therapy 
with warfarin and its effects on clinical outcomes.
Methods
Study design and study population
The WATER registry was designed as a mul-
ticenter, prospective, observational study with 
a baseline visit at the time of patient enrolment. 
Between September 2011 and January 2014 we en-
rolled AF patients undergoing warfarin therapy for 
≥ 6 months, who had been followed up and visited 
at an outpatient clinic by each institution. Patients 
were included if they were at least 18 years old and 
gave written informed consent for participation in 
the registry. The exclusion criteria were restricted 
to achieve a cohort close to real life. Furthermore, 
consecutive patients were included at each site 
in order to reduce selection bias. Only patients 
who did not give their informed consent and who 
did not comply with continuous warfarin therapy 
were excluded. Continuous warfarin therapy was 
defined as warfarin use without gaps exceeding 
2 months. The warfarin dose during the follow-up 
was adjusted to the therapeutic range proposed by 
the 2010 European Society of Cardiology (ESC) 
guidelines for the management of AF. All data were 
captured through an electronic case report form 
(eCRF). The first 7 days after treatment had started 
or restarted, time after permanent discontinuation 
of warfarin and time > 5 days from temporary dis-
continuation were not included in the calculation 
of TTR. Periprocedural (anticoagulation bridging) 
INR and/or daily INR values during hospitalization 
were also excluded. Patients on home-monitoring 
or home-management were not included in the 
registry. Follow-ups were performed by the at-
tending cardiologist with an office interview dur-
ing INR control visits to assess the occurrence of 
clinical outcomes and events, as well as patients’ 
compliance with warfarin therapy. The registry 
was performed according to the ethical principles 
of medical research involving human subjects, as 
specified in the Declaration of Helsinki.
Definitions
Event and status definitions were clearly 
defined on the eCRFs in order to achieve consist-
ency among participating centers. TTR definition 
was described above. The estimation of TTR was 
based on the INR ranges that have been defined 
for individual patient’s needs and clinical rationales 
(i.e. INR 2–3 for NVAF patients, INR 2.5–3.5 for 
valvular AF [VAF] patients with mitral prosthetic 
valve). Stroke was defined as a sudden onset of 
a focal neurologic deficit in a location consistent 
with the territory of a major cerebral artery. An 
event matching this definition but lasting less than 
24 h was considered a transient ischemic attack. 
Intracranial hemorrhage consisted of hemorrhagic 
stroke and subdural or subarachnoid hemorrhage. 
Systemic embolism was defined as abrupt vascular 
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insufficiency associated with clinical or radiologi-
cal evidence of arterial occlusion in the absence 
of another likely mechanism. Major bleeding was 
defined as a reduction in the hemoglobin level of 
at least 2 g/dL, a transfusion of at least 2 units of 
blood, or symptomatic bleeding in a critical area 
or organ. All other bleeding was considered minor. 
Duration of AF less than 7 days (with spontane-
ous return to sinus rhythm) or duration more than 
7 days distinguished paroxysmal from persistent AF. 
Hypertension was defined as blood pressure above 
140/90 mm Hg, diabetes as fasting blood glucose 
above 125 mg/dL, or the use of antihypertensive 
or antidiabetic drug therapy, respectively.
Statistical analysis
All variables collected in the eCRFs at base-
line and all derived parameters were used in the 
statistical analysis. Binary, categorical, and ordinal 
parameters were summarized by means of absolute 
and percentage numbers within the various catego-
ries. Numerical data were summarized by means 
of standard statistics (i.e. mean, standard devia-
tion, median, upper and lower quartile). Normally 
distributed continuous variables were expressed 
as mean (± standard deviation) and compared 
with unpaired Student’s t-test. Skewed variables 
were expressed as median (25–75 quartiles) and 
compared with the rank-sum test. Normality was 
assessed by the Shapiro-Wilk test. Differences 
between cohorts were tested for statistical sig-
nificance using the c2 test for categorical variables. 
Among-group comparisons were made using a non-
parametric test (Kruskal-Wallis test). Correlation 
analyses were carried out using parametric Pearson 
product-moment and nonparametric Spearman’s 
rank correlation test. A 2-sided p-value of < 0.05 
was considered statistically significant. The sta-
tistical analysis was performed using SAS v. 9.2.
Results
Patient characteristics
Between September 2011 and January 2014, 
of 986 patients screened, 572 (age 67.28 ± 12.4 
years, 59.96% female) met eligibility criteria and 
agreed to participate. Seventy percent of the study 
population had NVAF and 32% of the patients had 
paroxysmal AF. Clinical and demographic charac-
teristics of the study population, NVAF and VAF 
subgroups are shown in Table 1. The character-
istics of the NVAF subgroup demonstrated older 
and sicker (accumulated comorbidities such as 
hypertension, diabetes, coronary artery disease, 
Table 1. Demographic and clinical characteristics of the study population.
All patients
(n = 572)
VAF
(n = 169; 29.5%)
NVAF
(n = 403; 70.5%)
P
Age [years] 67.28 ± 12.4 61.44 ± 13 69.91 ± 10 < 0.001
Sex (female) 343 (60%) 116 (69%) 227 (56%) 0.0067
Body mass index [kg/m2] 27.77 ± 5.2 27.33 ± 4 27.96 ± 6 0.13
Paroxysmal AF 183 (32%) 24 (14%) 159 (39%) < 0.001
CHA2DS2VASc score – – 3.64 ± 1.53 –
HASBLED score – – 2.38 ± 1 –
Creatinine clearance [mL/min] 72.49 ± 51.3 79.76 ± 33 66.88 ± 26 < 0.001
Heart failure 202 (35.3%) 55 (33%) 147 (36%) 0.39
Hypertension 328 (57.3%) 71 (42%) 257 (64%) < 0.001
Diabetes mellitus 129 (22.5%) 23 (14%) 106 (26%) < 0.001
Coronary artery disease 160 (28%) 21 (12%) 139 (34%) < 0.001
Peripheral artery disease 50 (8.7%) 5 (3%) 45 (11%) < 0.001
MI history 68 (11.8%) 7 (4%) 61 (15%) < 0.001
CABG 55 (9.6%) 12 (7%) 43 (11%) 0.215
PCI 32 (5.5%) 2 (1%) 30 (7%) 0.0022
Stroke history 63 (11%) 14 (8%) 49 (12%) 0.19
Antiplatelet use 84 (14.7%) 23 (14%) 61 (15%) 0.364
VAF — valvular atrial fibrillation; NVAF — non-valvular atrial fibrillation; AF — atrial fibrillation; CABG — coronary artery bypass grafting;  
PCI — percutaneous coronary intervention
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reduced renal function etc.) patients than the VAF 
subgroup.
Quality of warfarin treatment and outcomes
TTR was calculated for all patients and separa - 
tely for subgroups. The mean follow-up time was 
46.9 ± 19 (median 22) months. During the follow-up 
period, the mean TTR for all patients on the 
WATER registry was 42.26% (median 40%). TTR 
value of NVAF and VAF subgroups was 40.3% and 
46.9%, respectively (p < 0.001). In terms of out- 
come events, there was no significant difference be-
tween the subgroups (Table 2). The study population 
was divided into two groups according to the me-
dian TTR level. Outcome event ratios of these 
groups are presented in Table 3. The TTR value 
≥ 40% group had lower death, minor bleeding and 
cardiac hospitalization ratios than the TTR value 
< 40% group. A correlation analysis showed a negative 
correlation between TTR value and age in the whole 
study population (r = –0.178, p < 0.001) (Fig. 1).
CHA2DS2VASc score and outcomes
Stroke risk was high in the NVAF sub-
group (mean CHA2DS2-VASc score of 3.6 ± 1.5). 
The NVAF group was dissected according to 
CHA2DS2VASc score and TTR values of these 
groups are presented in Figure 2. The median value 
of CHA2DS2VASc score was 4 in NVAF patients. 
The CHA2DS2VASc < 4 group had lower death, 
minor bleeding and cardiac hospitalization rates 
than the CHA2DS2VASc ≥ 4 group. They also had 
lower stroke and major bleeding rates than the 
CHA2DS2VASc ≥ 4 group but the differences were 
not statistically significant (Table 4). TTR value of 
CHA2DS2VASc ≥ 4 group was lower than the one of 
CHA2DS2VASc < 4 group and there was a negative 
correlation between the CHA2DS2VASc score and 
TTR value (r = –0.155, p = 0.018).
HASBLED score and bleeding events
The mean HASBLED score of the NVAF 
population was 2.38 ± 1 (median 3). Major bleed-
ing events were observed in 23 cases in the NVAF 
group. They had a higher HASBLED score than 
the patients without major bleeding, however the 
difference was not statistically significant (2.73 ± 1 
vs. 2.36 ± 1, p = 0.09). Minor bleeding events were 
observed in 158 cases in the NVAF group and they 
had a significantly higher HASBLED score than the 
cases without minor bleeding events (2.77 ± 0.9 
vs. 2.12 ± 1, p < 0.0001).
Table 2. Clinical events during follow-up.
All patients  
(n = 572)
VAF  
(n = 169; 29.5%)
NVAF  
(n = 403; 70.5%)
P
Follow-up duration (months-median) 24.21 ± 14 (22) 25.8 ± 16 (21) 23.5 ± 13 (22) 0.096
TTR [%] (median) 42.26 ± 18.4 (40) 46.89 ± 18.9 40.32 ± 17.8 < 0.001
Death 26 (4.55%) 6 (3.5%) 20 (5%) 0.52
Stroke/TIA 31 (5.4%) 7 (4%) 24 (6%) 0.43
Intracranial bleeding 2 (0.35%) 0 (0%) 2 (0.5%) 1
Major bleeding 29 (5.1%) 6 (3.5%) 23 (5.7%) 0.4
Minor bleeding 222 (38.8%) 64 (38%) 158 (39%) 0.78
Cardiac hospitalization 181 (31.6%) 53 (31%) 128 (32%) 1
VAF — valvular atrial fibrillation; NVAF — non-valvular atrial fibrillation; TTR — time in therapeutic range; TIA — transient ischemic attack
Table 3. Clinical events according to median time in therapeutic range (TTR) level.
TTR ≥ 40% (n = 318; 56%) TTR < 40% (n = 254; 44%) P
Death 11 (3.5%) 15 (5.9%) 0.0003
Stroke/TIA 18 (5.7%) 13 (5.1%) 0.14
Intracranial bleeding 2 (0.6%) 0 (0%) 1
Major bleeding 18 (5.7%) 11 (4.3%) 0.085
Minor bleeding 116 (36.5%) 106 (41.7%) < 0.0001
Cardiac hospitalization 91 (28.6%) 90 (35.4%) < 0.0001
TIA — transient ischemic attack
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Discussion
AF is the most common chronic rhythm dis-
order. It is present in over 4 million patients in 
Europe with a prevalence of 5–15% in patients 
over 80 years of age [1, 10]. Since AF carries 
certain morbidity, with ischemic stroke and other 
embolisms, during the last decade particular atten-
tion has been paid to the management of patients 
with AF. Several guidelines have been issued and 
proper anticoagulation treatment has been recom-
mended [2, 11, 12]. However, a large percentage of 
AF patients receive suboptimal care. Few studies 
have been conducted with similar prevalence and 
incidence ratios in the Turkish population [13, 14]. 
Notwithstanding this fact, a cohort study pointed 
Figure 2. Distribution of time in therapeutic range (TTR) levels according to CHA2DS2VASc score.
Figure 1. Correlation between age and time in therapeutic range (TTR) level.
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out that only 42% of eligible patients received 
oral anticoagulants [13]. Warfarin is a common 
anticoagulation strategy in Turkish patients with 
AF. However, there are no prospective, real life 
data about quality of anticoagulation control, fac-
tors which influence TTR values, the relationship 
between TTR value and clinical outcomes.
Registries are very important as means of 
identifying possible gaps between recommended 
therapies and actual everyday practice. National 
registries are always needed, since each country 
has specific features and data from other countries 
that may not apply elsewhere.
This registry aims to answer these questions 
in the Turkish population and exhibits unique 
results. The demographic profile of the registry 
population showed that nearly 70% of the AF 
population had non-valvular etiology. NVAF pa-
tients represented an older and sicker population 
than VAF population. These demographic char-
acteristics are compatible with the European and 
American registries except for a higher percentage 
of the VAF group in the whole AF population [10, 
15, 16]. These findings are unsurprising and com-
patible with a higher prevalence of acute rheumatic 
fever and rheumatic valve disease in Turkey, and 
also clearly exhibited that rheumatic heart disease 
and its late complications are still a public health 
concern in our country. Female dominancy was 
more evident in the VAF group than the NVAF 
group and NVAF patients had paroxysmal AF more 
often but had persistent and permanent AF less 
often than VAF patients. These demographic and 
clinical characteristics were previously validated 
in the EUROObservational Research Program on 
Atrial Fibrillation Pilot survey [1].
AF patients have a 5-fold increase in the risk of 
stroke and a 2-fold increase in the risk of mortality 
compared to individuals of the same age who are in 
sinus rhythm [2, 17]. The registry results show that 
AF patients have a 5-fold increase in stroke risk 
and a 4-fold increase in mortality compared to the 
general Turkish population [18–20]. The WATER 
registry showed that 1 in 3 patients was hospital-
ized due to cardiac causes and 4 in 10 patients had 
a minor bleeding event at their 2-year follow-up. 
These results reflected the health burden of AF 
in the Turkish population. However, these results 
should be evaluated cautiously according to the se-
lection bias of the registry. Although a consecutive 
enrolment and selection of ‘representative sites’ 
(outpatients and inpatients) was used to provide 
a real life data set, the WATER registry only enrolled 
AF patients undergoing warfarin therapy. Recent 
data have demonstrated that while 87% of the AF 
patients were high risk patients, only 42% of these 
patients were on oral anticoagulant treatment in 
Turkey [13]. In this context, higher stroke and 
mortality rates should not be a surprise in the real 
life setting of Turkey.
Warfarin is still the main anticoagulation strat-
egy for stroke prevention in Turkey but optimal use 
of warfarin in clinical practice is challenged by its 
narrow therapeutic window. Anticoagulation quality 
assessed by TTR has been closely associated with 
adverse outcomes, i.e., stroke, hemorrhage and 
mortality. In this registry, TTR levels were calcu-
lated on the basis of the INR ranges that have been 
defined for individual characteristics rather than 
simply assuming that the target range is 2.0–3.0. 
Although the VAF group had higher TTR values 
than NVAF, the registry demonstrated much poorer 
anticoagulation control in real life settings than 
similar European registries [10, 16]. As a result, 
patients were spending most of their time outside 
of the recommended therapeutic range. The effects 
Table 4. Baseline renal function, time in therapeutic range levels and clinical events according to  
median CHA2DS2VASc score.
CHA2DS2VASc score ≥ 4 (n = 205) < 4 (n = 198) P
Creatinine clearance [mL/dk] 57.2 ± 24.3 76.9 ± 24.3 < 0.001
TTR value [%] 38.3 ± 17.6 42.4 ± 17.8 0.019
Death 19 (9%) 1 (0.5%) < 0.001
Stroke/TIA 16 (8%) 8 (4%) 0.14
Intracranial bleeding 1 1 1
Major bleeding 16 (7.8%) 7 (3.5%) 0.085
Minor bleeding 116 (57%) 42 (21%) < 0.001
Cardiac hospitalization 98 (48%) 30 (15%) < 0.001
TTR — time in therapeutic range; TIA — transient ischemic attack
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of TTR on clinical outcomes were also confirmed 
in the registry.
Albeit a very low mean TTR level, the study 
population was divided into two groups according 
to median TTR of 40%. The lower TTR group had 
higher death, minor bleeding, and cardiac hospitali-
zation rates. Although major bleeding and stroke 
rates were similar between the two groups, lower 
event rates may have had a role in these results. 
The quality of anticoagulation was poorer in the 
older population and a negative correlation was 
evident between age and TTR level. These results 
have conflicted with previous similar registries. 
Witt et al. [21] identified that the older age group 
(age > 70) independently predicted INR stability. 
Similar results have been submitted by the VARIA 
Study which asserted that the group age > 55 had 
a predicted lower TTR [22]. However, both studies 
issued quality of anticoagulation control in patients 
who received oral anticoagulation for any indication 
(AF, venous thromboembolism, prosthetic valve 
etc.). Additionally, many previous studies which fo-
cused on AF population found old age to be associ-
ated with lower TTR [23, 24]. Possible explanations 
of the negative correlation between age and TTR 
are age related changes in drug metabolism, higher 
prevalence of co-morbidities in older patients, 
decline in cognitive function with increasing age 
and possible under treatment of the elderly with 
lower INR goals. Relationships between the older 
age, decreased renal function and lower TTR were 
also confirmed by the NVAF subgroup of WATER 
Registry. As an older group, NVAF patients may 
have lower cognitive function than the VAF group. 
We know that cognitive function has a main role 
in compliance of drug and INR visits. However, 
because the patients in the WATER Registry at-
tended cardiology clinics regularly and received 
specialized care, we believe that lower TTR was 
not a consequence of a lack of strict INR control or 
undertreatment of older patients with lower INR 
targets and patients’ access to healthcare.
Given the higher prevalence of co-morbidities 
in patients with NVAF, their potential association 
with lower TTR is of note. Anticoagulation control 
may be more challenging for patients with these 
co-morbidities. Nelson et al. [23] showed that heart 
failure, diabetes and previous strokes were asso-
ciated with the greatest likelihood of lower TTR. 
WATER results also confirmed the effects of renal 
function on anticoagulation control. The group 
whose mean TTR value was lower than the median 
level had lower creatinine clearance than the group 
whose mean TTR value was higher than the median 
level (67.4 ± 27 vs. 73.3 ± 30 mL/min respectively, 
p < 0.001). Furthermore, there was a significant 
positive correlation between the creatinine clear-
ance and TTR value (r = 0.137, p = 0.001). We 
know that heart failure, chronic kidney disease 
and diabetes affect the drug pharmacokinetics and 
finally pharmacodynamics. An additional explana-
tory mechanism is a possible interaction between 
warfarin and multiple drugs administered to these 
patients. These co-morbidities may also decline 
cognitive function, which affects drug compliance.
If good anticoagulation control cannot be 
achieved within the usual care setting, specialized 
anticoagulation management such as anticoagula-
tion clinics or handheld patient INR meters are 
validated alternative options [5, 25]. Finally, substi-
tution with newer oral anticoagulants is inevitable 
in patients with NVAF.
WATER results also proved that patients with 
a higher CHA2DS2VASc score were more likely to 
have a lower TTR level in the NVAF subgroup. We 
may hypothesize that factors contributing to the 
score have a major impact on drug metabolism, cog-
nitive function and finally INR stability. Although 
the score does not incorporate renal function, 
incorporated co-morbidities such as age, hyperten-
sion, diabetes, and vascular disease could be as-
sociated with concomitant chronic kidney disease, 
which is known to reduce anticoagulation stability. 
[5, 22–24]. The registry results confirmed the de-
terministic and prognostic role of CHA2DS2VASc 
score. Lower death, minor bleeding and cardiac 
hospitalization rates were observed in the group 
whose CHA2DS2VASc score, was higher than the 
median value. However there were no statistically 
significant differences between these groups in 
terms of major bleeding and stroke rates. Lower 
event rates, particularly major bleeding rates, 
may help assess the objectivity of these results. 
Additional dissecting the groups for higher than 
median value of CHA2DS2VASc score may result 
in the inadvertent, incorrect classification of many 
patients who had a higher risk of stroke as lower 
risk patients.
The value of the HASBLED score was also 
confirmed with the higher score of patients who 
had a minor bleeding event during the follow-up. 
Similarly with CHA2DS2VASc score, patients who 
had major bleeding had a statistically insignificant 
trend for higher HASBLED scores. As mentioned 
above, lower event rates may preclude reaching 
statistically significant differences.
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Limitations of the study
The study findings should be interpreted in the 
light of some limitations. Main limitations include 
the observational design; relatively small sample 
size, lower outcome rates (i.e. major bleeding, in-
tracranial bleeding etc.) and limited 2-year follow-
up. Because the registry included only 3 centers 
from the same city, results may not be reflective of 
the whole country and should not be generalized. 
As such, we cannot claim that our findings are 
clearly representative of warfarin management in 
other centers. Certainly a larger study conducted 
in more centers over different geographical regions 
would be desirable. Moreover, some of the data 
wre self-reported and therefore might not have 
been accurate. We could not assess scheduled 
interruptions of oral anticoagulants (i.e. peripro-
cedural bridging), which may have resulted in the 
underestimation of the TTR levels. Finally, because 
TTR values do not capture the full amplitude of 
INR fluctuations (either outside or within the 
therapeutic window), the TTR is a relatively crude 
measure of anticoagulation control. Lind et al. [26] 
showed that standard deviation of transformed INR 
is a better predictor of mortality, stroke, bleeding 
and hospitalization than the TTR in patients with 
AF receiving warfarin therapy. This approach may 
explain the difference of event ratios between the 
patients who had similar demographic profiles and 
TTR levels in WATER population.
Conclusions
In conclusion, the quality of anticoagulation 
with warfarin in daily clinical practice in Turkey 
is poor. This could have serious implications, as it 
is expected to adversely affect patient outcomes. 
These findings have implications for health policy. 
Strategies should be undertaken by the clinicians 
to improve TTR. Educational programs directed at 
patients are urgently needed to improve the qual-
ity of anticoagulation in Turkey. Frequent, even 
weekly, dose adjustments for the majority of INRs 
out of range is a simple concept that is associated 
with improved TTR and clinical outcome [27]. 
Systems that implement algorithm based dosing 
for AF patients on warfarin or widespread use of 
point of care testing devices for the measurement 
of INR may improve the management of patients 
[27–29]. If good anticoagulation control cannot be 
achieved with warfarin, new oral anticoagulants 
are inevitable strategies in patients with NVAF. 
Nevertheless, regarding the higher prevalence of 
valvular AF in Turkey than Europe and the United 
States, strategies should not be overlooked to 
improve TTR in these patients.
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